Tango Therapeutics' drug vopimetostat combined with daraxonrasib has shown a promising early signal in treating pancreatic cancer, based on a small group of 12 previously treated patients. A larger Phase 3 trial is planned to test the drug as a first-line treatment, but details on its design and regulatory approval are still uncertain. Additional studies in lung cancer and CNS cancers will reveal if the drug can succeed beyond this initial result. While the company has enough funding for now, key trials and potential market launch are still years away, making the stock a cautious hold for investors.
Chery unveiled its Globalisation 3.0 strategy at the 2026 International User Summit, aiming to transform from a traditional automaker into a high-tech integrated ecosystem by 2035. The strategy emphasizes AI adoption, green technologies, and local ma...
Unfair Links, founded by Rollo Unden and Oliver Fish, has launched a beta service providing local backlinks that are matched to a business's Google Business Profile, country, language, and page topic. Unlike generic backlinks, these links come from r...
Tango, a global live-streaming platform, has donated tens of thousands of dollars to support FRIDA Ukraine's mobile cancer screening program. This initiative brings essential cancer detection and preventive healthcare services directly to underserved...
California's upcoming AI safety mandate, effective May 15, 2027, is creating tension with federal military cybersecurity rules under the Defense Federal Acquisition Regulation Supplement (DFARS). Veteran-led engineering groups have developed advanced...
Greg Abel highlighted that every one-point increase in BNSF's profit margin translates to about $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational efficiency has on Berkshire's over...
